Success Metrics

Completion Rate

0%(0/3)

Active Trials

0(0%)

Terminated

3(100%)

Phase Distribution

Ph phase_1

67%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

2(66.7%)

Phase 2Efficacy & side effects

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Terminated(3)

Detailed Status

Terminated3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (66.7%)

Phase 21 (33.3%)

Trials by Status

terminated3100%

Recent Activity

0 active trials

Showing 3 of 3

terminatedphase_1

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

NCT02859415

terminatedphase_2

Mithramycin for Lung, Esophagus, and Other Chest Cancers

NCT01624090

terminatedphase_1

Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma

NCT01610570

Clinical Trials (3)

Showing 3 of 3 trials

NCT02859415Phase 1

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

Terminated

NCT01624090Phase 2

Mithramycin for Lung, Esophagus, and Other Chest Cancers

Terminated

NCT01610570Phase 1

Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3